PLX
Protalix BioTherapeutics Inc (PLX)
Healthcare • NYSE MKT • $1.94-2.02%
- Symbol
- PLX
- Exchange
- NYSE MKT
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $1.94
- Daily Change
- -2.02%
- Market Cap
- $156.31M
- Trailing P/E
- N/A
- Forward P/E
- 3.13
- 52W High
- $3.19
- 52W Low
- $1.32
- Analyst Target
- $11.00
- Dividend Yield
- N/A
- Beta
- -0.01
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. Protalix Bio…
Company websiteResearch PLX on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.